23andMe’s (ME) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a research report released on Saturday,Weiss Ratings reports.

23andMe Stock Performance

Shares of NASDAQ ME opened at $0.73 on Friday. 23andMe has a one year low of $0.73 and a one year high of $12.76. The firm has a market capitalization of $19.58 million, a P/E ratio of -0.05 and a beta of 1.19. The company’s fifty day moving average is $2.49 and its two-hundred day moving average is $3.89.

23andMe (NASDAQ:ME) last issued its earnings results on Tuesday, January 28th. The company reported ($1.02) earnings per share for the quarter. 23andMe had a negative return on equity of 170.07% and a negative net margin of 183.39%.

Institutional Trading of 23andMe

A number of institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of 23andMe by 24.0% in the third quarter. FMR LLC now owns 993,848 shares of the company’s stock valued at $345,000 after purchasing an additional 192,099 shares in the last quarter. Geode Capital Management LLC lifted its stake in 23andMe by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock valued at $1,476,000 after buying an additional 28,252 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in 23andMe during the 4th quarter valued at $26,000. MassMutual Private Wealth & Trust FSB acquired a new stake in 23andMe during the 4th quarter valued at $40,000. Finally, Leavell Investment Management Inc. purchased a new position in 23andMe during the fourth quarter worth $32,000. 36.10% of the stock is currently owned by hedge funds and other institutional investors.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.